SERA
Sera Prognostics, Inc. NASDAQ Listed Jul 15, 2021$1.75
-7.41%
vs $1.89
Mkt Cap $83.4M
52w Low $1.59
6.4% of range
52w High $4.09
50d MA $1.99
200d MA $2.69
P/E (TTM)
-2.6x
EV/EBITDA
—
P/B
1.1x
Debt/Equity
0.0x
ROE
-42.3%
P/FCF
-3.2x
RSI (14)
31.90
ATR (14)
$0.18
Beta
1.06
50d MA
$1.99
200d MA
$2.69
Avg Volume
76.3K
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
CIK (SEC)
Phone
801 990 0520
2749 East Parleys Way · Salt Lake City, UT 84109 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.16 | -0.17 | -6.2% | 1.81 | -5.5% | +6.1% | -2.1% | -8.0% | -2.3% | -5.9% | — |
| Mar 18, 2026 | AMC | -0.17 | -0.16 | +5.9% | 1.91 | -5.8% | -6.3% | +2.8% | -1.1% | +11.5% | -2.0% | — |
| Nov 13, 2025 | AMC | -0.19 | -0.16 | +15.8% | 2.95 | -4.1% | +0.3% | +3.4% | +2.0% | +2.6% | -2.2% | — |
| Aug 6, 2025 | AMC | -0.21 | -0.16 | +23.8% | 2.75 | -6.9% | -5.5% | -4.6% | -5.6% | -4.7% | +3.1% | — |
| May 7, 2025 | AMC | -0.24 | -0.20 | +16.7% | 2.40 | +1.2% | -11.7% | +4.7% | +4.5% | +1.3% | -4.3% | — |
| Mar 19, 2025 | AMC | -0.23 | -0.25 | -8.7% | 4.14 | +1.4% | -5.1% | -3.6% | +9.2% | -2.2% | -3.0% | — |
| Nov 6, 2024 | AMC | -0.22 | -0.24 | -9.1% | 8.74 | +0.0% | -12.7% | -11.7% | +10.4% | -2.7% | -3.7% | — |
| Aug 7, 2024 | AMC | -0.23 | -0.25 | -8.7% | 7.40 | -3.1% | +0.1% | -0.1% | -1.1% | -3.7% | -2.7% | — |
| May 8, 2024 | AMC | -0.23 | -0.25 | -8.7% | 9.30 | -1.0% | +5.3% | -5.4% | -1.7% | -8.2% | +1.0% | — |
| Mar 20, 2024 | AMC | -0.25 | -0.25 | +0.0% | 9.02 | -3.8% | +3.8% | +6.8% | -8.5% | +3.8% | -0.4% | — |
| Nov 8, 2023 | AMC | -0.30 | -0.23 | +23.3% | 1.97 | +1.0% | -7.6% | -7.1% | +4.1% | -1.7% | -2.9% | — |
| Aug 9, 2023 | AMC | -0.34 | -0.34 | +0.0% | 2.52 | +0.0% | +3.2% | -2.7% | -8.3% | -6.0% | -6.0% | — |
| May 10, 2023 | AMC | -0.35 | -0.34 | +2.9% | 3.48 | -0.3% | +0.6% | -0.9% | -1.2% | +0.6% | -1.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 4 | Craig Hallum | Initiates | Buy | $6 | $2.05 | $2.15 | +4.9% | +9.8% | +1.8% | -8.3% | +1.4% | -6.1% |
| Aug 10 | Citigroup | Maintains | Neutral → Neutral | — | $2.52 | $2.52 | +0.0% | +3.2% | -2.7% | -8.3% | -6.0% | -6.0% |
| Nov 10 | Citigroup | Maintains | Neutral → Neutral | — | $1.30 | $1.29 | -0.8% | +10.8% | +0.0% | -2.8% | +2.1% | +0.0% |
| Sep 14 | Berenberg | Maintains | Buy → Buy | — | $2.04 | $2.00 | -2.0% | -5.9% | -9.4% | -4.6% | +0.0% | +0.6% |
| Aug 29 | Oppenheimer | Maintains | Outperform → Outperform | — | $2.18 | $2.10 | -3.7% | -0.5% | +1.8% | -5.0% | -1.4% | -3.4% |
| Apr 27 | Berenberg | Maintains | Buy → Buy | — | $2.23 | $2.59 | +16.1% | +0.9% | -2.7% | +5.0% | -2.2% | -4.4% |
| Mar 30 | Citigroup | Downgrade | Buy → Neutral | — | $4.05 | $3.50 | -13.6% | -7.7% | +1.3% | -4.5% | -3.3% | -7.1% |
| Nov 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $10.54 | $10.65 | +1.0% | +2.5% | -0.1% | +1.4% | +0.5% | +0.0% |
| Aug 9 | Citigroup | Maintains | Buy → Buy | — | $12.89 | $12.74 | -1.2% | +1.2% | -3.8% | -1.8% | -5.1% | -7.9% |
| Aug 9 | TD Cowen | Maintains | Outperform → Outperform | — | $12.89 | $12.74 | -1.2% | +1.2% | -3.8% | -1.8% | -5.1% | -7.9% |
| Aug 9 | William Blair | Maintains | Outperform → Outperform | — | $12.89 | $12.74 | -1.2% | +1.2% | -3.8% | -1.8% | -5.1% | -7.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Jackson Benjamin | General Counsel | Sell | 2,179 | $2.01 | $4K | 161,756 | +1.09% | — |
| Jun 11, 2026 | Lindgardt Zhenya | Chief Executive Officer | Sell | 6,990 | $2.01 | $14K | 865,009 | +1.09% | — |
| Jun 11, 2026 | Aerts Austin | Chief Financial Officer | Sell | 2,037 | $2.01 | $4K | 301,190 | +1.09% | — |
| Jun 11, 2026 | Anderson Dyaarl Lee Jr. | Chief Commercial Officer | Sell | 4,739 | $2.01 | $10K | 77,998 | +1.09% | — |
| Jun 11, 2026 | Inglis Tiffany Eul Davis | Chief Medical Officer | Sell | 362 | $2.01 | $728 | 92,075 | +1.09% | — |
| Jun 9, 2026 | Lindgardt Zhenya | Chief Executive Officer | Sell | 20,755 | $2.08 | $43K | 871,999 | -3.50% | +1.61% |
| Jun 9, 2026 | Aerts Austin | Chief Financial Officer | Sell | 5,440 | $2.08 | $11K | 303,227 | -3.50% | +1.61% |
| Jun 8, 2026 | Lawrence Sandra AJ | — | Sell | 1,560 | $2.15 | $3K | 16,473 | -6.10% | +1.09% |
8-K
Sera Prognostics, Inc. -- 8-K Filing
Jun 4
8-K · 5.02
!!! Very High
Sera Prognostics, Inc. -- 8-K 5.02: Executive Change
Jun 1
8-K
Unknown — 8-K Filing
The landmark PRIME study publication validates PreTRM's clinical efficacy in reducing preterm births, positioning Sera for significant revenue expansion as commercial engagement accelerates across major U.S. markets.
Mar 18
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Aberdeen Group Plc | 2,550,775 | $5M | Added | Mar 2026 |
| 2 | Psp Research Llc | 2,396,685 | $5M | New | Mar 2026 |
| 3 | Vivo Capital, Llc | 1,650,440 | $3M | New | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 1,204,115 | $2M | New | Mar 2026 |
| 5 | Captrust Financial Advisors | 536,761 | $1M | — | Mar 2026 |
| 6 | Sanders Morris Harris Llc | 314,950 | $639K | New | Mar 2026 |
| 7 | Citadel Advisors Llc | 248,909 | $505K | Reduced | Mar 2026 |
| 8 | Morgan Stanley | 161,936 | $478K | Reduced | Dec 2025 |
| 9 | Jane Street Group, Llc | 68,826 | $203K | New | Dec 2025 |
| 10 | Northern Trust Corp | 96,535 | $196K | — | Mar 2026 |
| 11 | Millennium Management | 91,504 | $186K | Reduced | Mar 2026 |
| 12 | Perigon Wealth Management, Llc | 72,685 | $148K | — | Mar 2026 |
| 13 | Hightower Advisors, Llc | 42,234 | $125K | — | Dec 2025 |
| 14 | Bank Of New York Mellon Corp | 60,927 | $124K | Reduced | Mar 2026 |
| 15 | Requisite Capital Management, Llc | 55,648 | $113K | — | Mar 2026 |
| 16 | Twelve Points Wealth Management Llc | 43,388 | $88K | — | Mar 2026 |
| 17 | Barclays Plc | 31,967 | $65K | Reduced | Mar 2026 |
| 18 | Birch Hill Investment Advisors Llc | 27,293 | $55K | — | Mar 2026 |
| 19 | Catalyst Funds Management Pty Ltd | 23,564 | $48K | New | Mar 2026 |
| 20 | Two Sigma Investments, Lp | 21,964 | $45K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 12
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 160,431 | $367K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 79,210 | $161K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 50,639 | $116K | Feb 2026 |
| 4 | Fidelity Series Total Market Index Fund | 42,114 | $96K | Feb 2026 |
| 5 | Ultra-Small Company Market Fund | 41,105 | $83K | Mar 2026 |
| 6 | Fidelity Nasdaq Composite Index Fund | 23,191 | $53K | Feb 2026 |
| 7 | Schwab Total Stock Market Index Fund | 12,000 | $33K | Jan 2026 |
| 8 | Small Cap Core Fund | 10,320 | $21K | Mar 2026 |
| 9 | Avantis U.S. Small Cap Equity ETF | 5,403 | $12K | Feb 2026 |
| 10 | Victory Extended Market Index Fund | 2,659 | $7K | Jan 2026 |
| 11 | AST Small-Cap Equity Portfolio | 2,450 | $7K | Dec 2025 |
| 12 | Knights of Columbus U.S. ALL CAP INDEX FUND | 143 | $395 | Jan 2026 |
Valuation
Market Cap
$83.4M
Enterprise Value
$44.2M
P/E (TTM)
-2.61x
Forward P/E
—
PEG Ratio
0.14x
P/B
1.11x
P/S
1029.74x
P/FCF
-3.17x
EV/EBITDA
—
Shares Out
47.7M
Financials (TTM)
Revenue
$81K
Net Income
-$31.9M
EBITDA
-$35.6M
Free Cash Flow
-$26.3M
Op Cash Flow
-$25.6M
EPS Basic
$-0.67
EPS Diluted
$-0.67
EPS Forward
$-0.67
Gross Margin
-102.5%
Op Margin
-45066.7%
Net Margin
-39417.3%
Balance Sheet
Total Assets
$101.9M
Total Liab.
$26.5M
Total Equity
$75.4M
Cash
$39.2M
LT Debt
$0
Book Value/Sh
$1.58
Debt/Equity
0.03x
Current Ratio
1.69
Quick Ratio
1.69
Returns & Growth
ROE
-42.3%
ROA
-31.3%
ROIC
-46.9%
Rev Growth YoY
+5.2%
EPS Growth YoY
+32.3%
Price Returns
2W
+20.7%
1M
+11.3%
3M
-5.7%
6M
-35.1%
12M
+38.5%
Technicals
52W High
$4.09
52W Low
$1.59
50d MA
$1.99
200d MA
$2.69
RSI (14)
31.90
ATR (14)
$0.18
Beta
1.06
Avg Volume
76K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$5.00
High
$5.00
Low
$5.00
Median
$5.00
Data updated apr 27, 2026 12:46am
· Source: financialmodelingprep.com